Suppr超能文献

每日一次服用阿替洛尔、尼群地平及其联合用药治疗轻至中度原发性高血压的比较。

Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension.

作者信息

Maclean D, Mitchell E T, Lewis R, Irvine N, McLay J S, McEwen J, Coulson R R, Slater N D, Fitzsimons T J, McDevitt D G

机构信息

University Department of Clinical Pharmacology, Ninewells Hospital, Dundee.

出版信息

Br J Clin Pharmacol. 1990 Apr;29(4):455-63. doi: 10.1111/j.1365-2125.1990.tb03664.x.

Abstract
  1. The aim of the study was to compare the efficacy and the tolerability of treatment with atenolol (50-100 mg once daily), nitrendipine (20-40 mg once daily) and their combination (atenolol 50 mg + nitrendipine 20 mg) once daily in patients with mild to moderate essential hypertension. 2. The study was a randomised, double-blind, placebo controlled parallel groups design: blood pressures were measured at 'trough' effect (i.e. 24 h after dosing) to assess the adequacy of once-daily treatment. 3. Mean blood pressures (mm Hg) recorded on four occasions over 12 weeks of treatment were significantly lower both with atenolol (155/97 sitting: 155/104 standing) and with the combination of atenolol plus nitrendipine (153/96 sitting: 152/104 standing) than with placebo (169/108 sitting: 169/114 standing). Nitrendipine alone had no significant effect on blood pressure 24 h after dosing (165/104 sitting: 165/110 standing). 4. Withdrawals due to adverse effects were more common during treatment with nitrendipine: 7/32 of the patients experienced adverse effects attributable to intense systemic vasodilatation (e.g., flushing, erythema, headache). 2/37 patients taking atenolol were withdrawn: one because he developed a psoriatic rash and the other because of impaired peripheral circulation. Of the 35 patients taking combination treatment, two were withdrawn: one developed headaches and dyspnoea, and the other asthma. 5. The results suggest that once daily dosing with nitrendipine does not control blood pressure throughout the 24 h period in the majority of patients, and is associated with a considerable burden of adverse effects. Combination treatment was better tolerated but appeared to offer no advantages over atenolol alone in terms either of blood pressure control or adverse effects.
摘要
  1. 本研究的目的是比较阿替洛尔(每日一次,50 - 100毫克)、尼群地平(每日一次,20 - 40毫克)及其联合用药(阿替洛尔50毫克 + 尼群地平20毫克)每日一次治疗轻度至中度原发性高血压患者的疗效和耐受性。2. 本研究采用随机、双盲、安慰剂对照平行组设计:在“谷”效应(即给药后24小时)测量血压,以评估每日一次治疗的充分性。3. 在治疗的12周内四次记录的平均血压(毫米汞柱),阿替洛尔组(坐位155/97:立位155/104)和阿替洛尔加尼群地平联合用药组(坐位153/96:立位152/104)均显著低于安慰剂组(坐位169/108:立位169/114)。单独使用尼群地平在给药24小时后对血压无显著影响(坐位165/104:立位165/110)。4. 尼群地平治疗期间因不良反应停药更为常见:32例患者中有7例出现因强烈的全身血管扩张所致的不良反应(如潮红、红斑、头痛)。服用阿替洛尔的37例患者中有2例停药:1例因出现银屑病皮疹,另1例因外周循环受损。在35例接受联合治疗的患者中,2例停药:1例出现头痛和呼吸困难,另1例出现哮喘。5. 结果表明,大多数患者每日一次服用尼群地平在24小时内无法控制血压,且不良反应负担较重。联合治疗耐受性较好,但在血压控制或不良反应方面似乎并不比单独使用阿替洛尔更具优势。

相似文献

1
Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension.
Br J Clin Pharmacol. 1990 Apr;29(4):455-63. doi: 10.1111/j.1365-2125.1990.tb03664.x.
9
Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.
Br J Clin Pharmacol. 1988 Apr;25(4):425-31. doi: 10.1111/j.1365-2125.1988.tb03325.x.

本文引用的文献

2
Haemodynamic effects of nifedipine in essential hypertension at rest and during exercise.
J Hypertens. 1983 Aug;1(2):159-63. doi: 10.1097/00004872-198308000-00008.
3
Role of nifedipine in treatment of hypertension.
Br Med J (Clin Res Ed). 1983 Jul 23;287(6387):257-9. doi: 10.1136/bmj.287.6387.257.
4
Use of calcium antagonists as monotherapy in the management of hypertension.
Am J Med. 1984 Aug 31;77(2B):11-5. doi: 10.1016/s0002-9343(84)80079-0.
5
Adverse reactions to calcium antagonists.
Drugs. 1983 Feb;25(2):196-222. doi: 10.2165/00003495-198325020-00006.
10
Atenolol plus nifedipine for mild to moderate systemic hypertension after fixed doses of either agent alone.
Am J Cardiol. 1986 Apr 15;57(11):965-70. doi: 10.1016/0002-9149(86)90740-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验